Literature DB >> 16931592

Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay.

Shoichi Matsukuma1, Mitsuyo Yoshihara, Fumio Kasai, Akinori Kato, Akira Yoshida, Makoto Akaike, Osamu Kobayashi, Haruhiko Nakayama, Yuji Sakuma, Tsutomu Yoshida, Yoichi Kameda, Eiju Tsuchiya, Yohei Miyagi.   

Abstract

A simple and rapid method to detect the epidermal growth factor receptor hot spot mutation L858R in lung adenocarcinoma was developed based on principles similar to the universal heteroduplex generator technology. A single-stranded oligonucleotide with an internal deletion was used to generate heteroduplexes (loop-hybrids) bearing a loop in the complementary strand derived from the polymerase chain reaction product of the normal or mutant allele. By placing deletion in the oligonucleotide adjacent to the mutational site, difference in electrophoretic mobility between loop-hybrids with normal and mutated DNA was distinguishable in a native polyacrylamide gel. The method was also modified to detect in-frame deletion mutations of epidermal growth factor receptor in lung adenocarcinomas. In addition, the method was adapted to detect hot spot mutations in the B-type Raf kinase (BRAF) at V600 and in a Ras-oncogene (NRAS) at Q61, the mutations commonly found in thyroid carcinomas. Our mutation detection system, designated the loop-hybrid mobility shift assay was sensitive enough to detect mutant DNA comprising 7.5% of the total DNA. As a simple and straightforward mutation detection technique, loop-hybrid mobility shift assay may be useful for the molecular diagnosis of certain types of clinical cancers. Other applications are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931592      PMCID: PMC1867624          DOI: 10.2353/jmoldx.2006.060030

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Imatinib mesylate--a new oral targeted therapy.

Authors:  David G Savage; Karen H Antman
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

3.  Rapid detection of exon 1 NRAS gene mutations using universal heteroduplex generator technology.

Authors:  Carolina Belli; Carlos De Brasi; Irene Larripa
Journal:  Hum Mutat       Date:  2003-02       Impact factor: 4.878

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

6.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

7.  BRAF mutation in papillary thyroid carcinoma.

Authors:  Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

8.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  BRAF and RAS mutations in human lung cancer and melanoma.

Authors:  Marcia S Brose; Patricia Volpe; Michael Feldman; Madhu Kumar; Irum Rishi; Renee Gerrero; Eugene Einhorn; Meenhard Herlyn; John Minna; Andrew Nicholson; Jack A Roth; Steven M Albelda; Helen Davies; Charles Cox; Graham Brignell; Philip Stephens; P Andrew Futreal; Richard Wooster; Michael R Stratton; Barbara L Weber
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

View more
  15 in total

1.  Stromal micropapillary pattern predominant lung adenocarcinoma--a report of two cases.

Authors:  Miki Ohe; Tomoyuki Yokose; Yuji Sakuma; Sachie Osanai; Chikako Hasegawa; Kota Washimi; Kimitoshi Nawa; Tetsukan Woo; Rurika Hamanaka; Haruhiko Nakayama; Yoichi Kameda; Kouzo Yamada; Takeshi Isobe
Journal:  Diagn Pathol       Date:  2011-09-29       Impact factor: 2.644

2.  Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.

Authors:  Yuji Sakuma; Hirotaka Nishikiori; Sachie Hirai; Miki Yamaguchi; Gen Yamada; Atsushi Watanabe; Tadashi Hasegawa; Takashi Kojima; Toshiro Niki; Hiroki Takahashi
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

3.  Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.

Authors:  Tetsuya Isaka; Hiroyuki Ito; Haruhiko Nakayama; Tomoyuki Yokose; Kayoko Katayama; Kouzo Yamada; Munetaka Masuda
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

4.  The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.

Authors:  G D A Brandao; E F Brega; A Spatz
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

5.  New point mutation in Golga3 causes multiple defects in spermatogenesis.

Authors:  L F Bentson; V A Agbor; L N Agbor; A C Lopez; L E Nfonsam; S S Bornstein; M A Handel; C C Linder
Journal:  Andrology       Date:  2013-03-15       Impact factor: 3.842

6.  Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma.

Authors:  Miki Ohe; Tomoyuki Yokose; Yuji Sakuma; Yohei Miyagi; Naoyuki Okamoto; Sachie Osanai; Chikako Hasegawa; Haruhiko Nakayama; Yoichi Kameda; Kouzo Yamada; Takeshi Isobe
Journal:  Diagn Pathol       Date:  2012-01-06       Impact factor: 2.644

7.  Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.

Authors:  F Oshita; S Matsukuma; M Yoshihara; Y Sakuma; N Ohgane; Y Kameda; H Saito; K Yamada; E Tsuchiya; Y Miyagi
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

8.  MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF.

Authors:  Zhenlei Wang; Bin Ma; Xiaopin Ji; Yang Deng; Tao Zhang; Xiaojian Zhang; Haoji Gao; Hanxing Sun; Haoxuan Wu; Xianze Chen; Ren Zhao
Journal:  Cancer Cell Int       Date:  2015-04-15       Impact factor: 5.722

9.  Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.

Authors:  Matheus M de Gunst; Marielle I Gallegos-Ruiz; Giuseppe Giaccone; Jose Antonio Rodriguez
Journal:  Mol Cancer       Date:  2007-09-18       Impact factor: 27.401

10.  SNP (-617C>A) in ARE-like loci of the NRF2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women.

Authors:  Yasuko Okano; Uru Nezu; Yasuaki Enokida; Ming Ta Michael Lee; Hiroko Kinoshita; Alexander Lezhava; Yoshihide Hayashizaki; Satoshi Morita; Masataka Taguri; Yasushi Ichikawa; Takeshi Kaneko; Yutaka Natsumeda; Tomoyuki Yokose; Haruhiko Nakayama; Yohei Miyagi; Toshihisa Ishikawa
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.